HC Q study #47
See all studies
6/10
Positive
Early treatment study
Otea et al., medRxiv, doi:10.1101/2020.06.10.20101105 (Preprint)
A short therapeutic regimen based on hydroxych loroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications.
80 moderate cases, HC Q+AZ appears to reduce serious complications and death. Moderate treated cases resulted in hospitalization at the same rate as mild untreated cases suggesting efficacy.
Source   Share   Tweet
See all studies
Please send us corrections, updates, or comments.
Submit